

NDA 204781/S-014

SUPPLEMENT APPROVAL

Guerbet/Liebel-Flarsheim Company LLC
Attention: Alpa Jain
Senior Regulatory Associate
821 Alexander Road, Suite 204
Princeton, NJ 08540

Dear Alpa Jain:

Please refer to your supplemental new drug application (sNDA) dated October 13, 2023, received, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Dotarem® (gadoterate meglumine) Injection and DOTAREM® (gadoterate meglumine) Pharmacy Bulk Package.

We also refer to our letter dated September 13, 2023, notifying you, under 21 CFR 208.24(d), you are responsible for ensuring that the label of each container or package includes a prominent and conspicuous instruction to authorized dispensers to provide a Medication Guide to each patient to whom the drug is dispensed, and states how the Medication Guide is provided. We requested you submit a supplement with marked up carton and container labels of all strengths and formulations with the required statement alerting the dispenser to provide the Medication Guide.

These “Changes Being Effectuated” sNDAs provides for carton and container labeling of all strengths and formulations with the required statement alerting the dispenser to provide the Medication Guide.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA #####/S-###**.” Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21CFR 314.80 and 314.81).

If you have any questions, please contact Rene Tyson, Safety Regulatory Project Manager, at (301) 796-1476.

Sincerely,

{See appended electronic signature page}

Anil Rajpal, M.D., M.P.H.
Deputy Director for Safety
Division of Imaging and Radiation Medicine
Office of Specialty Medicine
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ANIL K RAJPAL
08/14/2024 12:08:44 AM